vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and Shimmick Corp (SHIM). Click either name above to swap in a different company.

Shimmick Corp is the larger business by last-quarter revenue ($141.9M vs $74.7M, roughly 1.9× Health Catalyst, Inc.). Shimmick Corp runs the higher net margin — -3.1% vs -121.9%, a 118.8% gap on every dollar of revenue. Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $-28.7M). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -10.1%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

Shimmick Corp is a U.S.-based heavy civil construction firm specializing in building and upgrading critical public infrastructure, including water facilities, transportation systems, dams, and environmental remediation projects. It primarily serves federal, state, and local government clients across North America, delivering complex large-scale construction solutions for public sector segments.

HCAT vs SHIM — Head-to-Head

Bigger by revenue
SHIM
SHIM
1.9× larger
SHIM
$141.9M
$74.7M
HCAT
Higher net margin
SHIM
SHIM
118.8% more per $
SHIM
-3.1%
-121.9%
HCAT
More free cash flow
HCAT
HCAT
$38.4M more FCF
HCAT
$9.6M
$-28.7M
SHIM
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-10.1%
SHIM

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
HCAT
HCAT
SHIM
SHIM
Revenue
$74.7M
$141.9M
Net Profit
$-91.0M
$-4.4M
Gross Margin
7.6%
Operating Margin
-115.3%
-2.2%
Net Margin
-121.9%
-3.1%
Revenue YoY
-6.2%
Net Profit YoY
-340.3%
EPS (diluted)
$-1.29
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
SHIM
SHIM
Q4 25
$74.7M
$141.9M
Q3 25
$76.3M
$128.4M
Q2 25
$80.7M
$122.1M
Q1 25
$79.4M
$103.6M
Q4 24
$79.6M
Q3 24
$76.4M
$166.0M
Q2 24
$75.9M
$90.6M
Q1 24
$74.7M
$120.0M
Net Profit
HCAT
HCAT
SHIM
SHIM
Q4 25
$-91.0M
$-4.4M
Q3 25
$-22.2M
$-8.5M
Q2 25
$-41.0M
$-9.8M
Q1 25
$-23.7M
$-38.5M
Q4 24
$-20.7M
Q3 24
$-14.7M
$-1.6M
Q2 24
$-13.5M
$-51.4M
Q1 24
$-20.6M
$-33.3M
Gross Margin
HCAT
HCAT
SHIM
SHIM
Q4 25
7.6%
Q3 25
52.6%
6.3%
Q2 25
3.8%
Q1 25
-20.1%
Q4 24
Q3 24
47.5%
7.3%
Q2 24
-34.4%
Q1 24
-13.2%
Operating Margin
HCAT
HCAT
SHIM
SHIM
Q4 25
-115.3%
-2.2%
Q3 25
-22.9%
-5.5%
Q2 25
-46.0%
-7.3%
Q1 25
-25.4%
-39.3%
Q4 24
-22.0%
Q3 24
-17.9%
0.7%
Q2 24
-20.8%
-53.0%
Q1 24
-30.5%
-26.5%
Net Margin
HCAT
HCAT
SHIM
SHIM
Q4 25
-121.9%
-3.1%
Q3 25
-29.1%
-6.6%
Q2 25
-50.8%
-8.0%
Q1 25
-29.9%
-37.1%
Q4 24
-26.0%
Q3 24
-19.3%
-0.9%
Q2 24
-17.8%
-56.7%
Q1 24
-27.6%
-27.8%
EPS (diluted)
HCAT
HCAT
SHIM
SHIM
Q4 25
$-1.29
$-0.12
Q3 25
$-0.32
$-0.25
Q2 25
$-0.59
$-0.28
Q1 25
$-0.35
$-0.92
Q4 24
$-0.33
Q3 24
$-0.24
$-0.05
Q2 24
$-0.23
$-1.83
Q1 24
$-0.35
$-1.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
SHIM
SHIM
Cash + ST InvestmentsLiquidity on hand
$95.7M
$17.6M
Total DebtLower is stronger
$153.3M
$57.5M
Stockholders' EquityBook value
$245.8M
$-52.7M
Total Assets
$502.6M
$218.5M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
SHIM
SHIM
Q4 25
$95.7M
$17.6M
Q3 25
$91.5M
$21.4M
Q2 25
$97.3M
$16.3M
Q1 25
$342.0M
$33.7M
Q4 24
$392.0M
Q3 24
$387.3M
$26.0M
Q2 24
$308.3M
$22.4M
Q1 24
$327.8M
$27.3M
Total Debt
HCAT
HCAT
SHIM
SHIM
Q4 25
$153.3M
$57.5M
Q3 25
$153.1M
$36.4M
Q2 25
$153.0M
$31.4M
Q1 25
$382.9M
$9.5M
Q4 24
$382.4M
Q3 24
$345.0M
$39.9M
Q2 24
Q1 24
$31.5M
Stockholders' Equity
HCAT
HCAT
SHIM
SHIM
Q4 25
$245.8M
$-52.7M
Q3 25
$331.9M
$-49.5M
Q2 25
$347.5M
$-42.6M
Q1 25
$376.8M
$-34.7M
Q4 24
$365.2M
Q3 24
$355.0M
$973.0K
Q2 24
$357.0M
$436.0K
Q1 24
$357.2M
$38.1M
Total Assets
HCAT
HCAT
SHIM
SHIM
Q4 25
$502.6M
$218.5M
Q3 25
$587.1M
$203.0M
Q2 25
$616.2M
$227.7M
Q1 25
$891.5M
$233.9M
Q4 24
$858.9M
Q3 24
$813.0M
$346.7M
Q2 24
$691.7M
$344.5M
Q1 24
$695.1M
$378.0M
Debt / Equity
HCAT
HCAT
SHIM
SHIM
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
41.01×
Q2 24
Q1 24
0.83×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
SHIM
SHIM
Operating Cash FlowLast quarter
$9.9M
$-23.7M
Free Cash FlowOCF − Capex
$9.6M
$-28.7M
FCF MarginFCF / Revenue
12.9%
-20.2%
Capex IntensityCapex / Revenue
0.4%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K
$-27.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
SHIM
SHIM
Q4 25
$9.9M
$-23.7M
Q3 25
$-464.0K
$-3.8M
Q2 25
$-9.0M
$-38.2M
Q1 25
$280.0K
$44.9M
Q4 24
$-3.5M
Q3 24
$6.2M
$12.7M
Q2 24
$1.6M
$-43.9M
Q1 24
$10.3M
$-35.0M
Free Cash Flow
HCAT
HCAT
SHIM
SHIM
Q4 25
$9.6M
$-28.7M
Q3 25
$-719.0K
$-4.2M
Q2 25
$-9.2M
$-38.7M
Q1 25
$-390.0K
$44.4M
Q4 24
$-3.9M
Q3 24
$5.5M
$10.3M
Q2 24
$1.3M
$-46.8M
Q1 24
$10.1M
$-39.6M
FCF Margin
HCAT
HCAT
SHIM
SHIM
Q4 25
12.9%
-20.2%
Q3 25
-0.9%
-3.2%
Q2 25
-11.4%
-31.7%
Q1 25
-0.5%
42.9%
Q4 24
-4.9%
Q3 24
7.2%
6.2%
Q2 24
1.7%
-51.7%
Q1 24
13.5%
-33.0%
Capex Intensity
HCAT
HCAT
SHIM
SHIM
Q4 25
0.4%
3.5%
Q3 25
0.3%
0.3%
Q2 25
0.3%
0.4%
Q1 25
0.8%
0.5%
Q4 24
0.5%
Q3 24
0.9%
1.4%
Q2 24
0.4%
3.3%
Q1 24
0.3%
3.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

SHIM
SHIM

Shimmick Projects$106.8M75%
Non Core Projects$35.1M25%

Related Comparisons